The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3

CD123 became a therapeutic target for acute myelocytic leukemia(AML) because of its overexpression only on AML stem cells. It is α subunit of interleukin-3 (multi-CSF, IL3) receptor. Lidamycin(LDM) is a novel antibiotic composed of an apoprotein (LDP) and a chromophore (AE). We cloned, expressed and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Biol Ther
Main Authors: Zhang, Yanjun, Liu, Rong, Fan, Dongmei, Shi, Rizan, Yang, Ming, Miao, Qingfang, Deng, Zhao-Qun, Qian, Jun, Zhen, Yongsu, Xiong, Dongsheng, Wang, Jianxiang
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2015
Assuntos:
Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846095/
https://ncbi.nlm.nih.gov/pubmed/26186454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1071733
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares